Clinical Trial Update: Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating intrathecal dual PD-1 and CTLA-4 checkpoint inhibition with pemetrexed for leptomeningeal metastasis; recruitment is on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis

Drugs mentioned

• CTLA-4 inhibitor (intrathecal)
• PD-1 inhibitor (intrathecal)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Guangzhou Medical University | Conditions: Leptomeningeal Metastasis, Pemetrexed | Phase 1, Phase 2 | Status: RECRUITING